Vapotherm, Inc. (VAPO)

OTCMKTS: VAPO · Delayed Price · USD
1.330
+0.008 (0.57%)
Mar 27, 2024, 3:54 PM EDT - Market closed
Market Cap 8.24M
Revenue (ttm) 68.67M
Net Income (ttm) -58.19M
Shares Out 6.19M
EPS (ttm) -8.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 20,470
Open 1.390
Previous Close 1.323
Day's Range 1.330 - 1.400
52-Week Range 0.750 - 7.440
Beta -1.15
Analysts Sell
Price Target 1.00 (-24.81%)
Earnings Date Nov 8, 2023

About VAPO

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers High Velocity Therapy systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, and Precision Flow Classic which delivers non-invasive ventilatory support to patients by providing heated, humidified, and oxygenated air at a high velocity to treat patients thro... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Nov 14, 2018
Employees 182
Stock Exchange OTCMKTS
Ticker Symbol VAPO
Full Company Profile

Financial Performance

In 2023, Vapotherm's revenue was $68.67 million, an increase of 2.80% compared to the previous year's $66.80 million. Losses were -$58.19 million, -48.62% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for VAPO stock is "Sell" and the 12-month stock price forecast is $1.0.

Price Target
$1.0
(-24.81% downside)
Analyst Consensus: Sell
Stock Forecasts

News

Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)

Partnership enables Vapotherm to build a robust and secure solution 80% faster than the standard development timeline to meet data visualization and device management goals for HVT® 2.0 and future Hom...

8 days ago - PRNewsWire

Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE

EXETER, N.H. , March 15, 2024 /PRNewswire/ -- Vapotherm, Inc., (OTCQX: VAPO), ("Vapotherm" or the "Company") today announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTR...

13 days ago - PRNewsWire

Dr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherm's High Velocity Therapy effectively treats moderate-severe acute exacerbations of COPD, while improving patient comfort

EXETER, N.H. , March 6, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm" or the "Company") today announced that David Yamane, MD was awarded the Star Research Award by the Society for ...

22 days ago - PRNewsWire

Vapotherm's HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South America's Largest Health Care Market

EXETER, N.H. , Feb. 29, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm" or the "Company"), a global medical technology company specializing in the development and commercialization of...

4 weeks ago - PRNewsWire

Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial Results

EXETER, N.H. , Feb. 22, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm" or the "Company"), today announced fourth quarter and fiscal year 2023 financial results and related highlights...

4 weeks ago - PRNewsWire

Vapotherm Announces Suspension of NYSE Listing Common Stock Expected to Begin Trading Promptly on OTCQX

EXETER, N.H. , Dec. 14, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced it has received notice that the New York Stock Exchange ("NYSE") has determine...

3 months ago - PRNewsWire

NYSE to Commence Delisting Proceedings Against Vapotherm, Inc. (VAPO)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of V...

3 months ago - Business Wire

Vapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock Application Pending to Transfer Shares to OTCQX

EXETER, N.H. , Dec. 11, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced its intention to voluntarily delist its common stock from The New York Stock E...

3 months ago - PRNewsWire

Vapotherm Educates over 8,000 Clinicians in Respiratory Care Month

EXETER, N.H. , Nov. 28, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high veloci...

4 months ago - PRNewsWire

Vapotherm Reports Third Quarter 2023 Financial Results

EXETER, N.H. , Nov. 8, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced third quarter 2023 financial results and related highlights.

5 months ago - PRNewsWire

Vapotherm To Report Third Quarter 2023 Financial Results

EXETER, N.H. , Nov. 1, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the third quarter of 2023 after the...

5 months ago - PRNewsWire

Computational Fluid Dynamics (CFD) modeling further distinguishes Vapotherm High Velocity Therapy from generic high flow cannulas

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® pr...

6 months ago - Business Wire

Pilot Study demonstrates Vapotherm HVNI technology is more effective than standard oxygen therapy for treatment of acute asthma in children

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® pr...

6 months ago - Business Wire

Vapotherm Reports Second Quarter 2023 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced second quarter 2023 financial results. Second Quarter 2023 Summary and Highlights Net reven...

8 months ago - Business Wire

Vapotherm To Report Second Quarter 2023 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced that it will release financial results for the second quarter of 2023 after the close of tr...

8 months ago - Business Wire

Vapotherm Reports First Quarter 2023 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced first quarter 2023 financial results. First Quarter 2023 Summary and Highlights Total reven...

11 months ago - Business Wire

Vapotherm To Report First Quarter 2023 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced that it will release financial results for the first quarter of 2023 after the close of tra...

11 months ago - Business Wire

Vapotherm Announces NYSE Continued Listing Standard Notice Related to Stock Price

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vap...

1 year ago - Business Wire

Vapotherm Reports Fourth Quarter and Fiscal Year 2022 Financial Results

EXETER, New Hampshire--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced fourth quarter and fiscal year 2022 financial results. Fourth Quarter 2022 Summary...

1 year ago - Business Wire

Vapotherm Announces Closing of $23 Million Private Placement

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc.

1 year ago - Business Wire

Vapotherm Announces $23 Million Private Placement

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc.

1 year ago - Business Wire

Vapotherm Reports Preliminary Fourth Quarter and Full Year 2022 Results and Year-End Cash Balance

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vap...

1 year ago - Business Wire

Vapotherm Announces Amendment to Debt Agreement

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary V...

1 year ago - Business Wire

Vapotherm Reports Third Quarter 2022 Financial Results

EXETER, N.H.

1 year ago - Business Wire

Vapotherm to Report Third Quarter 2022 Financial Results

EXETER, N.H.

1 year ago - Business Wire